CHIRON VITRASERT TIME TO PROGRESSION IS 194 DAYS IN PHASE III TRIAL; OPHTHALMIC IMPLANT RECOMMENDED FOR APPROVAL BY FDA ADVISORY COMMITTEE
• By The Pink Sheet
Chiron Vision's sterile intravitreal ganciclovir implant Vitrasert increases time to progression of cytomegalovirus retinitis by 112 days compared to I.V. ganciclovir, according to studies presented at FDA's Ophthalmic and Dermatologic Advisory Committee meeting Dec. 8.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.